Actinobac Biomed focuses on the development of pharmaceutical technologies derived from agents that target Leukocyte Function Antigen-1 (LFA-1).
The company's lead product, Leukotoxin, is a bacterial toxin that specifically targets white blood cells. In addition to its use as an effective targeted therapy agent for the treatment of hematologic malignancies, abundant evidence in literature suggests that Leukotoxin, or a derived product, can effectively be used to treat infectious diseases such as HIV/AIDS and tuberculosis, as well as many autoimmune diseases including rheumatoid arthritis, multiple sclerosis, Crohnâ€™s disease, type 1 diabetes, Lupus and psoriasis.
Therefore, the company will direct its efforts in three strategic areas. The first, and highest priority, is the development of Leukotoxin as a protein therapeutic for the treatment of hematologic malignancies. The second will focus on the use of Leukotoxin and derived therapeutic peptides or mimetics for the treatment of significant diseases other than hematologic malignancies, including infections and autoimmune diseases. The third area represents an early-stage drug discovery program with Magellan BioScience that will maintain a healthy pipeline of novel therapeutic agents.
Funding Rounds (2) - $600kUpdate
Current Team (2)Update
|May 29, 2015||PRNewswire All - Actinobac Biomed Receives $905,000 Small Business Grant from NCI to Advance Blood Cancer Research|
|Dec 17, 2013||Wired News - Here's How You Can Help Fund Sensational Research Projects|
|Dec 17, 2013||Wired News - Here’s How You Can Help Fund Sensational Research Projects|
|Feb 23, 2013||FinSMEs - Actinobac Biomed Raises $100K in Seed Financing|
|Feb 22, 2013||PRNewswire All - Foundation Venture Capital Group Commits Second Round of Funding to Actinobac... -- NEW BRUNSWICK, N.J., Feb. 21, 2013 /PRNewswire-USNewswire/ --|
|Jun 22, 2009||VentureDeal - Actinobac Biomed Receives Venture Capital Commitment|
Actinobac Biomed, Inc.
675 US Highway 1
North Brunswick, NJ 08902